Metsera

Metsera's MET-233i demonstrated up to 8.4% placebo-subtracted weight loss at Day 36 in a Phase 1 trial of 80 participants with overweight or obesity.

Metsera's ultra-long-acting amylin injection MET-233i demonstrated 8.4% placebo-adjusted weight loss at 36 weeks in Phase I trial with once-monthly dosing.

Metsera will present clinical data from its completed Phase 1/2 trial of MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, at the 85th Scientific Sessions of the American Diabetes Association.

Metsera is seeking a $289 million IPO to fund the Phase III trial of its lead candidate, MET-097i, an injectable GLP-1 receptor agonist for obesity.

Metsera reported promising Phase II data for its investigational subcutaneous GLP-1 therapy, positioning it as a potential acquisition target.

Metsera's MET-097i, an ultra-long acting GLP-1 receptor agonist, showed substantial placebo-adjusted weight loss of up to 11.3% after 12 weeks in a Phase 2a trial.

• Metsera's MET-097i, an ultra-long-acting GLP-1 receptor agonist, demonstrated a 7.5% body weight reduction in a Phase I/II trial. • The trial, conducted at Altasciences' facility, also revealed a 380-hour half-life for MET-097i, supporting its potential for monthly dosing. • Based on these results, Metsera has initiated a 16-week Phase II trial to further evaluate the efficacy and safety of MET-097i. • Altasciences supported Metsera's broader drug development program, including work on amylin analog MET-233i and oral GLP-1 agonist MET-002.

Metsera has secured $215 million in Series B financing to advance its portfolio of Nutrient-Stimulated Hormone (NuSH) analog peptides for obesity and metabolic diseases.

Eli Lilly's Zepbound demonstrated superior weight loss compared to Novo Nordisk's Wegovy in a head-to-head trial, with Zepbound users losing over 20% of body weight versus Wegovy's under 14%.

Metsera raised $215 million in a Series B funding round to advance its portfolio of GLP-1 receptor agonists for weight loss, bringing its total funding to over $500 million.